www.sltrib.com

www.sltrib.com
Share

www.sltrib.com

 •  February 18

Risky drug importation legislation now being considered at the state Capitol not only threatens to open the door to dangerous counterfeit medicines, but it could also dampen job growth in Utah’s vibrant, dynamic life-sciences industry. The experts and entrepreneurs who lead Utah’s 1,300 life-sciences companies deeply understand the desire to bend...

www.sltrib.com

 •  January 22

House Speaker Greg Hughes opened the 2018 Legislature on Monday by declaring war on opiate drugmakers for doing little to prevent addiction — and by urging part-time legislators to seek more power against the full-time governor. The Draper Republican said he became upset with the manufacturers of opiates when he opened an office in the Rio Grande...

www.sltrib.com

 •  September 22, 2017

As the debate over repeal and replace of the Affordable Care Act (ACA), better known as Obamacare, winds its way through the halls of Congress, one thing is clear: Health care costs are out of control and something must be done to rein them in. While untangling the regulations of the ACA and freeing up market competition among health plans will go...

www.sltrib.com

 •  April 29, 2017

This image provided by Novartis shows Rydapt. The Food and Drug Administration on Friday approved Rydapt for treating adults newly diagnosed with acute myeloid leukemia who have a genetic mutation called FLT3. Patients would take it along with chemotherapy. The drug, known chemically as midostaurin, is the first new medicine for acute myeloid...

www.sltrib.com

 •  February 14, 2017

Mylan's biggest shareholder is backing the generic drugmaker's plan to remain a stand-alone company as it fights a takeover bid from larger rival Teva Pharmaceutical. Abbott Laboratories also says it will vote its nearly 15 percent stake in Mylan in favor of that company's proposed Perrigo acquisition bid, which is valued at around $34...